机器人袖式肺叶切除术治疗中心型非小细胞肺癌:与胸腔镜和开胸手术的倾向评分加权比较
该研究纳入2012至2017年188例接受袖式肺叶切除术的中心型非小细胞肺癌患者,比较机器人(49例)、胸腔镜(73例)与开胸(66例)三种术式。经倾向评分加权匹配后,三组90天死亡率与并发症无统计学差异;机器人组出血量、手术时间和引流时间更少,且无支气管切缘阳性或中转开胸。多因素分析显示手术方式与总生存和无病生存均无独立关联。
要点
- 机器人袖式肺叶切除术安全可行,肿瘤学预后与胸腔镜和开胸相当。
- 机器人组出血量、手术时间和引流时间均少于胸腔镜和开胸组。
- 三组90天死亡率与并发症无统计学差异,机器人组无切缘阳性或中转。
核心结论
- 机器人袖式肺叶切除术是安全、可行且有效的手术方式。
- 与胸腔镜和开胸相比,机器人袖式肺叶切除术治疗中心型非小细胞肺癌的肿瘤学预后相似。
- 需更大样本量和长期随访的进一步研究。
研究设计与样本
- 回顾性比较研究,纳入2012至2017年188例接受袖式肺叶切除术的非小细胞肺癌患者。
- 分为机器人组(n=49)、胸腔镜组(n=73)和开胸组(n=66)。
- 采用倾向评分加权匹配平衡三组基线,保留全部患者。
- 使用χ2检验、Fisher精确检验和Kruskal-Wallis秩和检验评估手术结局。
- 使用Log-rank检验和Cox比例风险模型进行生存分析。
主要发现
- 加权匹配后三组90天死亡率和并发症无统计学差异。
- 机器人组出血量少于其他两组(P < .001)。
- 机器人组手术时间短于其他两组(P < .001)。
- 机器人组引流时间短于其他两组(P < .001)。
- 机器人组无支气管切缘阳性或中转开胸。
临床怎么用
- 对于中心型非小细胞肺癌需行袖式肺叶切除术者,机器人手术可作为安全可行的选择。
- 机器人袖式肺叶切除术在围手术期指标上可能优于胸腔镜和开胸,且肿瘤学预后相似。
局限性
- 样本量有限(188例),需更大样本研究验证。
- 随访时间有限,需长期随访结果。
- 为回顾性研究,尽管采用倾向评分加权,仍可能存在残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the surgical and oncologic outcomes of robotic sleeve lobectomy in comparison with video-assisted thoracoscopic surgery (VATS) and open surgery. METHODS: Surgical outcomes in patients with non-small cell lung cancer who underwent sleeve lobectomy via robotic, VATS, and thoracotomy were assessed using the χ2 test, Fisher exact test, and the Kruskal-Wallis rank sum test. Log-rank test and Cox proportional hazards model were used in survival analyses. Propensity score-weighted matching was used to achieve the balance of baseline among the 3 groups. RESULTS: Between 2012 and 2017, 188 patients were included and divided into robotic (n = 49), VATS (n = 73), and open (n = 66) groups. After weighted matching that retained all patients, no statistical difference in 90-day mortality or morbidity among the 3 groups was shown. Patients in the robotic group had less bleeding loss (P < .001), operative time (P < .001), and tube drainage time (P < .001) than the other 2 groups. No positive bronchial margin or conversion presented in the robotic group. In multivariable analyses, surgical technique was independently associated with neither overall survival nor disease-free survival (P > .050). CONCLUSIONS: Robotic sleeve lobectomy is a safe, feasible, and effective procedure. Compared with VATS and open techniques, robotic sleeve lobectomy has a similar oncologic prognosis for patients with centrally located non-small cell lung cancer. Further studies with a larger sample size and long-term follow-up are needed.
引用
- Qiu T, Zhao Y, Xuan Y, et al. Robotic sleeve lobectomy for centrally located non-small cell lung cancer: A propensity score-weighted comparison with thoracoscopic and open surgery. J Thorac Cardiovasc Surg. 2019. PMID: 31924355. doi:10.1016/j.jtcvs.2019.10.158
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。